SCHEMBL246958

SCHEMBL246958

COc1ccc(-c2cnc(N3CCOCC3)cc2N)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 1/20 0.49
MAP4K1 Q92918 3/20 0.48
PDE10A Q9Y233 1/20 0.47
FYN P06241 1/20 0.46
KIT P10721 2/20 0.44
PIK3CA P42336 2/20 0.44
MTOR P42345 2/20 0.44
CNR2 P34972 1/20 0.44
RAF1 P04049 2/20 0.44
BRAF P15056 2/20 0.44
ERN1 O75460 1/20 0.44
JUN P05412 1/20 0.44
MAPK8 P45983 1/20 0.44
MAPK10 P53779 1/20 0.44
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
LRRK2 Q5S007 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GAK O14976 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL252272 0.88 ALK (0.47) ALKMAP4K1CNR2LRRK2
SCHEMBL248047 0.87 GRM2 (0.44) ALKMAP4K1PIK3CAMTORCNR2
SCHEMBL3410821 0.83 CNR2 (0.49) FYNCNR2ERN1
SCHEMBL248108 0.82 PIK3CA (0.49) ALKPIK3CAMTORCNR2
SCHEMBL248634 0.82 FYN (0.48) ALKMAP4K1PDE10AFYNKIT
SCHEMBL246130 0.81 LRRK2 (0.50) MAP4K1PDE10AFYNPIK3CAMTOR
SCHEMBL3995999 0.80 LRRK2 (0.52) MAP4K1PIK3CAMTORRAF1BRAF
SCHEMBL246984 0.80 CYP2C19 (0.52) ALKMAP4K1PDE10AFYNPIK3CA
SCHEMBL5564075 0.78 CYP2C19 (0.54) ALKMAP4K1PDE10AFYNKIT
SCHEMBL246131 0.76 CYP2C19 (0.59) ALKPDE10APIK3CAMTORLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588471-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 ALK 502/4885MAP4K1 775/4885PDE10A 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.